Drug intelligence / Profile preview

interleukin-3

Development stage
Phase 1
Lead developer
Amgen
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous
01

Overview

Interleukin-3 (IL-3) is a cytokine and hematopoietic growth factor primarily secreted by activated T lymphocytes, mast cells, and osteoblastic cells. It regulates the production, proliferation, differentiation, and activation of hematopoietic progenitor cells into lineage-restricted blood cell types. IL-3 also stimulates mature basophils, eosinophils, and monocytes to become functionally activated. Mechanistically, IL-3 exerts its effects through a receptor composed of the IL3RA subunit and a signal-transducing subunit (IL3RB), leading to rapid activation of JAK2 kinase activity and STAT5-mediated transcriptional programs[1][5]. Clinically studied as recombinant human interleukin 3 for use in patients with bone marrow failure or after myelotoxic chemotherapy or bone marrow transplantation to enhance platelet and neutrophil recovery[6][7][10]. It has also been investigated for its immunomodulatory roles in autoimmune diseases such as arthritis, diabetes (especially type 1), systemic lupus erythematosus (SLE), as well as potential applications in cancer immunotherapy due to its ability to modulate cytotoxic T lymphocyte–basophil crosstalk[4][8].

Other names
Hematopoietic growth factorMultipotential colony-stimulating factor
02

Targets

IL3RA (Interleukin 3 Receptor)JAK2 (Janus kinase 2)STAT5A (STAT5)

Beyond the preview

Go deeper on interleukin-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-3.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call